Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What Future For Genentech's Lebrikizumab On Phase III Failure?

This article was originally published in Scrip

Executive Summary

Roche/Genentech's IL-13 inhibiting investigational severe asthma product lebrikizumab has failed in one of its two pivotal trials, adding to reservations about its future. Lebrikizumab is already trailing other biological competitors to the market and the lack of robust data at Phase III could well spell the end in this indication.

You may also be interested in...



Almirall Extends Dermatology Reach With Dermira Lebrikizumab Deal

Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.

Asthma Pipeline Pressure For AstraZeneca As STRATOS 1 Fails

The failure of AstraZeneca's novel asthma therapy in its first pivotal trial is of little surprise but increases the pressure on its other late-stage asthma product in this key therapy area for the company.

Teva Gets EU Green Light For Reslizumab

Teva is set to get its severe asthma treatment Cinqaero onto the EU market following a positive opinion from the CHMP but, as in the US, its label will restrict its use to adult patients.

Related Content

Topics

UsernamePublicRestriction

Register

SC064628

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel